Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 1/12
Home » Web Exclusives » Prostate Cancer Management Across America
Prostate Cancer Care Rebounding After COVID-19 Disruption
Jody A. Charnow
Routine and nonessential healthcare services came to a nearly complete halt in many places
throughout the United States as a result of the coronavirus disease 2019 (COVID-19) pandemic.
Hospitals and medical practices discontinued or substantially curtailed provision of all but the most
necessary procedures. Fearing infection with the novel coronavirus that causes COVID-19, many
patients avoided contact with the healthcare system. Caseloads dropped precipitously across
physician specialties.
Physicians who manage patients with prostate cancer (PCa) have not been spared. Urologists, for
example, have had to postpone performing prostate biopsies and radical prostatectomies (RPs) except
in the most urgent cases. In interviews with Renal & Urology News, urologists and medical oncologists
across the nation explained their PCa caseloads, which plummeted for a few months early in the
pandemic, have rebounded substantially even in areas that were severely impacted by COVID-19
outbreaks.
New York City
Those hard hit places include New York City, which quickly emerged as the nation’s pandemic
epicenter. As early as April 1, for example, the city’s health department reported a total of 45,707
con�rmed COVID-19 cases and 1374 deaths. Those numbers soared to 164,505 and 13,000,
respectively, by April 30, and further swelled to 229,980 and 19,042, respectively, as of August 30.
Patients with COVID-19 overwhelmed hospitals. All but the most urgent medical procedures were
September 1, 2020
1
1
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 2/12
C O N T I N U E R E A D I N G
postponed. Physicians with Integrated Medical Professionals, parent company of Advanced Urology
Centers of New York and Advanced Radiation Centers of New York, an independent group with
headquarters in Farmingdale, New York, and a clinical af�liate of The Mount Sinai Health System in
New York, New York, can attest to how COVID-19 hampered PCa care.
Prior to the pandemic, urologists in the group performed around 1000 prostate biopsies a quarter,
said urologist Deepak A. Kapoor, MD, the group’s chairman and chief executive of�cer. For a few
months after the pandemic struck, the number of these biopsies plunged to only a few per week, he
said.
Today’s Top Picks for You on Renal and Urology News
Dr Kapoor pointed out that prostate biopsies can result in sepsis, the most signi�cant complication of
the procedure, as well as bleeding and urinary retention. Patients may require hospitalization if these
problems occur. This would mean using hospital resources when they were badly needed to care for
COVID-19 patients. “As a result, we felt that it was our moral obligation to not do elective prostate
biopsies,” he explained. “As a consequence, many of those biopsies were delayed.”
However, the group is now ramping up prostate biopsies, Dr Kapoor said. He estimates that his group
is at 75% to 80% of the prostate biopsy volume they had before the pandemic. A return to normal
biopsy caseloads was delayed in part because patient anxiety about contracting COVID-19 kept
individuals from undergoing the procedure, he said. Another factor was the availability of procedure
room time “because we still try to do biopsies transperineally, our ability to do the procedure is a little
bit restricted,” Dr Kapoor related.
Dr Kapoor said his group moved quickly to establish safety protocols. During the second week of
March, the group formed a COVID-19 task force that had representatives from every specialty and
service department. “We pulled together as a team in amazing collective fashion in a very short period
of time to create protocols that would enable us to continue to function clinically while keeping our
employees and our patients safe … and most importantly, out of the hospital.”
“Our goal during the pandemic was to keep our patients out of the hospital because if you have a trip
to the hospital you’re in big trouble,” said Ann E. Anderson, MD, the group’s director of pathology. Not
only would patients be at risk of contracting COVID-19, they might not have a bed or stretcher
available to lie on, she said.
Reopening Your Practice: 10 Tips for Navigating a Complex Process
Hydroxychloroquine Lowers Death Risk in COVID-19 Cases
Priorities in Prostate Cancer Care During the Pandemic
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 3/12
Dr Anderson and her pathology colleagues developed a virtual laboratory methodology whereby
physicians could order laboratory tests via telemedicine. This way, patients could go to diagnostic
testing sites in their community rather than have to travel to one of the group’s of�ces.
The group was able to increase caseloads largely because of COVID-19 testing, Dr Anderson said. “We
were extremely proactive in COVID testing during the height of the pandemic for our staff,” she said.
“That was a very big boost to the staff morale and the company’s ability to provide care for the
patients.”
Longer-Duration Hormonal Injections
During the height of the pandemic in New York City, Dr Kapoor related, some patients with PCa who
were faced with postponement of RPs opted instead to have radiation therapy rather than delay
treatment. Other patients with PCa were given androgen deprivation therapy (ADT) as a stopgap
measure until they could undergo RP, Dr Kapoor said. For patients with advanced PCa, urologists gave
6-month, rather than 3-month, injections of hormonal therapy to increase the interval between
patient visits. The only patients with PCa for whom care changed little during the pandemic were
those with castration-resistant disease. As they are high-risk patients, “we had no choice but to bring
them in on a regular basis to make sure they were adequately followed,” Dr Kapoor said.
Telehealth played a big part in cutting down on the number of face-to-face encounters with patients,
he said. His group went from having no telehealth encounters on March 12 to nearly 2000 telehealth
encounters a week by the end of March. “I don’t know what we would have done had we not been able
to at least communicate with those patients virtually,” he said.
The expanded use of telehealth was enabled in large part by the Centers for Medicare and Medicaid
Services (CMS), which issued waivers that gave greater �exibility in the use of this modality and
established payment parity between telehealth and regular in-person clinical care for Medicare
patients.
‘Semblance of Normalcy’
UroPartners, LLC, a large urology group practice that serves the Chicago area, experienced a 70%
decline in patient visits early during the pandemic, but the situation has improved substantially, said
the group’s president and chief executive of�cer, Richard Harris, MD, who also is president of the
Large Urology Group Practice Association (LUGPA). In-of�ce visits bounced back much faster than he
expected, he said. “We’re back up to 98% of our pre-COVID numbers,” Dr Harris explained, adding that
his group �gured out how to work around the dif�culties posed by the pandemic so they could keep
everybody safe while providing care. He credits telehealth for enabling providers in his group to “stay
in the loop” with many patients. “The ability to do telemedicine has had a profoundly positive impact
on our ability to treat these patients,” Dr Harris said.
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 4/12
Dr Harris said his group’s surgicenter is handling more cases than ever because many patients do not
want to undergo procedures in a hospital for fear of COVID-19. As elsewhere, RPs were put off for a
couple of months, but the number of these procedures began rising around May or June.
“I think most people are getting back up to speed as far as patient care,” said Dr Harris. “It’s not quite
business as usual. I don’t know that it’s ever going to be until we have a vaccine or this [virus] has gone
away. But at least we’re back to some semblance of normalcy.”
Paci�c Northwest
PCa care also appears to be rebounding in the Washington State and the Paci�c Northwest in general,
according to Daniel W. Lin, MD, professor and chief of urologic oncology at the University of
Washington in Seattle, where he also is director of the Institute for Prostate Cancer Research. The
COVID-19 outbreak in Washington State — which had 74,320 con�rmed COVID-19 cases and 1905
related deaths as of August 30 — was not as severe as in New York City, but during the height of the
outbreak from mid-March to the end of April the “center basically stopped doing biopsies for routine
elevated PSA,” Dr Lin explained. The same was true for most, if not all, of the Paci�c Northwest.
“Patients, we think, probably were not hurt by a few-month delay,” he said.
Discontinuation of prostate biopsies for several months, however, has led to a decline in new PCa
diagnoses, he noted.
There was a period of a few months when many hospitals nationwide were discouraging or postponing
surgeries and radiation therapy for lower-risk PCa, not only to protect patients and staff from COVID-
19 transmission, but also out of concern about running out of PPE and other resources that might be
needed for live-saving COVID-19 care. At the University of Washington, some robotic RPs for low-risk
PCa were postponed because of concern about using up resources.
Still, patients have been reluctant to make medical visits, and this has devastated primary care
practices, according to Dr Lin. “Patients are fearful of seeing their healthcare provider. They are not
seeking general medical care, and thus are not getting screened for prostate cancer.” This fact has led
to a decrease in patient referrals to urologists because of elevated PSA.
Even though Oregon, another Paci�c Northwest state, had a relatively mild COVID-19 outbreak (with
26,554 and 458 con�rmed cases and deaths as of August 30 ) compared with New York City and some
other cities, COVID-19 altered medical care.
“We had a statewide halt on nonessential medical procedures that ended on May 1,” said medical
oncologist Tomasz M. Beer, MD, professor of medicine at the Oregon Health & Science University
(OSHU) in Portland, where he is deputy director of the OHSU Knight Cancer Institute. “During that
time, prostate biopsies and even prostatectomies except for very aggressive cases were viewed as
nonessential cases. But medical treatment for advanced cancer was universally treated as essential.
2
3
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 5/12
We did not delay any hormonal therapy or chemotherapy or immunotherapy. And we did not delay
participation and treatment in clinical trials. We were able to continue most of our clinical research.”
Routine visits for prostate cancer screening had largely been put on hold during March through May,
and even men with elevated PSA may have delayed seeing urologists to arrange for a biopsy, Dr Beer
said. Men who had a low-grade cancer found on a prepandemic biopsy may have held off on treatment
because they know there generally is no urgency with these tumors. But caseloads are essentially back
to what they were before the pandemic. “We’re all real busy again now,” he said.
Physicians at the institute transitioned many patient encounters to a virtual setting, Dr Beer said. “We
see a lot of our patients by video [or] by phone if they have no access to video. But if they need
injections or infusions or imaging or blood tests, we have facilities set up to accommodate that, and
they’ve continued to receive their treatment as scheduled.”
As a result of the COVID-19 crisis, Dr Beer explained that physicians made adjustments in speci�c PCa
treatments. For example, during the pandemic, most patients on hormonal therapy were switched to
6-month injections from 1-, 3-, and 4-month injections to decrease the number of patient visits.
Miami-Dade County
In one of the newest COVID-19 hotspots, Florida’s Miami-Dade County (which as of August 30 had
156,038 and 2399 con�rmed COVID-19 cases and deaths, respectively ), the outbreak prompted
changes in how physicians at Sylvester Comprehensive Cancer Center in Miami provided PCa care as
early as April.
“For a couple of weeks to a month beginning around mid-April, everything almost shut down
completely,” said urologic oncologist Sanoj Punnen, MD, associate professor of urology at the
University of Miami’s Miller School of Medicine. “We’ve had to restructure a lot of what we do.”
Prior to the pandemic, he saw patients from 8 AM to 5 PM, but now he sees them from 8 AM to noon,
with priority given to patients he “really needs to see in person for any acute issues and procedures.”
Clinic staff schedule appointments to ensure patients do not wait around with others. Patients wait in
their cars until they receive a phone call telling them a clinic room is available for their appointment.
His afternoons in clinic are spent conducting telehealth visits for patients he does not need to see in
person. As a result of how his clinic functions, patients generally do not experience delays in care, he
said. “If a patient needs a biopsy, he can get it done pretty much as [if] we were at full capacity,” Dr
Punnen said.
A Busy Period for Medical Oncologists
Even in Minnesota, which was not especially hard hit by the pandemic, physicians had to alter their
usual care of patients with PCa as a precaution, notably in March and April, according to Arpit Rao,
4
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 6/12
MBBS, an assistant professor in the Division of Hematology, Oncology and Transplantation at the
University of Minnesota in Minneapolis. Dr Rao leads the genitourinary oncology clinical research
program and the oncology quality and safety team for M Health Fairview system. According to Dr Rao,
some patients facing delayed RP or radiation therapy were placed on a few months of ADT as a
therapeutic bridge until they could receive de�nitive treatment. The medical oncology department
became busier during the pandemic, Dr Rao said, a trend he suspects is due in part to postponed PCa
surgeries. Given the delay, men sought consultations with medical oncologists “just to make sure
they’re exploring all the options,” he said.
“Before the pandemic, we had probably 16 to 20 patients in a day of clinic,” Dr Rao said. “During the
pandemic, the volume has been 20% to 30% higher.”
For patients with metastatic PCa, he took steps to space visits farther apart when the pandemic hit. “I
used to see everybody about once a month for oral novel antiandrogen therapy; now I see them every
6 to 8 weeks at this point,” Dr Rao said. “Whereas we used to get imaging every 3 months, now it’s
every 4 to 6 months. Whether that’s going to have long-term consequences remains to be seen. But in
the short term, we haven’t really experienced any signi�cant increases in complication rates.” For some
patients already on ADT, he switched from 3-month to 6-month injections to decrease the number of
patient visits.
Surgeries Resume ‘At Full Pace’
Although the pandemic led to an RP backlog, the situation has begun to normalize, according to Dr
Rao. “We have been able to resume surgeries at full pace, as before the pandemic,” he said.
He kept in touch with many patients via telehealth, which he found useful but not optimal in some
cases. “After the pandemic started, 80% of our visits were virtual,” he explained. “The pandemic
offered us a glimpse into the future of oncology care and allowed us to understand the characteristics
of patients and services that can be safely and effectively transitioned to a telehealth model, and of
those for whom the traditional care model would continue to be the best approach.”
Telehealth is a major part of how City of Hope, a comprehensive cancer center in Duarte, California, is
managing patients with PCa during the pandemic. “COVID-19 has led many patients to be hesitant to
come see their doctors due to perceived fear of exposure to the novel coronavirus,” said medical
oncologist Yung Lyou, MD, PhD. As a result, patients undergoing chronic PSA surveillance or who were
not on any active treatments that require a clinic visit — such as leuprolide injections or chemotherapy
infusions — have asked to be converted to telehealth encounters.
“While City of Hope had a telemedicine program prior to the pandemic, the current situation
prompted us to rapidly accelerate our planned telemedicine program expansion,” he said.
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 7/12
Reassuring Patients by Phone
Increased use of telehealth was just one of the effects of the COVID-19 outbreak. Dr Lyou said he had
to reassure patients by telephone that his institution had strict infection-control measures in place to
prevent COVID-19 transmission. “Many of my patients have felt anxious,” he said, “so I have had to
make quite a few phone calls to inform them that at City of Hope, where the focus is primarily cancer
patients, we take very strict precautions to limit the spread of COVID-19 within our facility. For
example, I detail how all staff and patients are screened with a detailed questionnaire and
temperature check prior to admission into the cancer center. Also, everyone is required to wear a
mask and if they show up without one, we will issue a medical grade facemask at the door.”
Dr Lyou said physicians and other staff at City of Hope have been fortunate in that their leadership has
maintained adequate levels of personal protective equipment (PPE) for everyone. Additionally, drive-
through COVID-19 testing is readily available on the Duarte campus, with an approximately 4-hour
turnaround time. “We perform in-house COVID-19 screening prior to all surgical procedures or
hospital admissions,” Dr Lyou said. “These measures have greatly helped to limit our COVID-19
infection rates.”
To lower the risk of COVID-19 transmission, the City of Hope medical center limits the number of
visitors. “In the pre-COVID era, we used to see patients with their family members or caregivers,” he
said. “However, due to COVID-19 visitor restrictions, with few exceptions, only the patient is allowed
to enter the clinic for visits. As a workaround, we have been using telephone or videoconferencing
with the other family members while we see patients to ensure everyone is included in the medical
decision making [process].”
Dr Lyou said he has had to educate patients with PCa about their risk of contracting COVID-19. One
of the most common questions I get asked is, ‘As a prostate cancer patient, do I have a higher risk for
COVID-19 compared to the general population?’”
He informs patients on chemotherapy that they may be at higher risk for infection because their
treatment causes myelosuppression, but explains to ADT recipients that no de�nitive evidence exists
showing that ADT causes immunosuppression. “As a result, they are most likely at the same risk as
someone in their age group without prostate cancer,” he said.
Rami�cations of Delayed Care
Whether the delays in care caused by the pandemic will have an effect on PCa outcomes is unclear.
Urologists and oncologists generally agree that deferring such medical procedures as prostate
biopsies and prostate surgery for a few months will likely have no signi�cant effect on oncologic
outcomes in patients with low-risk PCa. As Dr Kapoor pointed out, PCa is generally a slow growing
cancer compared with other genitourinary malignancies. “Frankly, I am much more worried about my
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 8/12
patients with renal cell carcinoma and my patients with bladder cancer who may not have been able to
come in than I am worried about the patients with prostate cancer,” he said.
Nevertheless, he said, “It would be naive to believe that there were some patients whose pathology
didn’t advance.”
Although the pandemic interrupted routine follow-up care such as PSA tests and prostate biopsies for
patients on active surveillance, Dr Harris said, most of these patients have low- or very low-risk
cancer, “so a month or two probably isn’t going to make any difference as far as outcomes or changes
in their disease pattern.”
Dr Punnen observed that patients with PCa usually do not need acute care, even those with
metastatic disease on ADT. “If they miss receiving their ADT injection by a month or so, “it’s probably
not going to have a huge impact,” Dr Punnen said.
Dr Rao pointed out, however, that many men are skipping primary care visits and not having PSA tests
that could detect subclinical PCa. “They may end up presenting with locally advanced disease,” he said.
Men with advanced PCa and asymptomatic bone metastases, especially those with aggressive disease,
may progress to symptomatic disease and present with cancer-related complications as a result of
putting off follow-up care for a few months, he said.
Prostate Cancer Research
As with patient care, the pandemic has had an effect on PCa research, but to varying degrees across
the United States. At the Sylvester Comprehensive Cancer Center, clinical research slowed “because
obviously research isn’t given the same priority as clinical care,” Dr Punnen said. Many research
coordinators are still working from home, and that has had an impact on clinical trial accrual. “We
don’t really have the resources to get [patients] enrolled in trials and follow through with care,” Dr
Punnen said. “As a result, I don’t think we’re seeing the accruals that we normally would.” He added,
however, that the situation is “getting better week by week, and we’re almost back to where we used
to be.”
The pandemic curtailed much of the PCa research at the University of Washington, which had to
suspend a number of clinical trials because of concern about exposing patients to the COVID-19
coronavirus, Dr Lin said. These studies included dose-�nding phase 1 trials and phase 3 trials where a
“nonexperimental equivalent” treatment is available, he said. One of these phase 3 trials is SWOG
1802, which is being conducted at sites throughout the United States. The trial is comparing standard
systemic therapy alone (the nonexperimental equivalent) with standard systemic therapy plus
de�nitive treatment (RP or radiation) of the primary tumor (the experimental therapy) in patients with
metastatic PCa.
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 9/12
The pandemic has had less of an effect on clinical research at OSHU. “By and large, we were able to
both continue to treat patients on study and continue new enrollments into treatment studies,” Dr
Beer said. Investigators discontinued some non-treatment studies in which there was no clear bene�t
to patients. Earlier in the pandemic, they stopped projects that involved gathering patient samples
solely for laboratory research and had no direct effect on patient care, but these projects have since
resumed, he said.
At the University of Minnesota, COVID-19 had minimal effect on PCa research, according to Dr Rao. “I
think we’ve been very successful at keeping the pace of clinical research going,” he said, adding that his
institution’s research program has actually grown in terms of enrollment.
“We’ve been able to publish, we’ve been able to contribute to [U.S. Food and Drug Administration]
approvals despite the pandemic,” Dr Rao said. “But there have been challenges. At one point, we were
basically doing twice as much paperwork to get every single enrollment. Enrollments were halted
university-wide, and you had to convince 3 tiers of research personnel to get a patient into a clinical
trial.”
He added, “Our patients have been very committed to clinical research. Many of them have been
committed knowing full well that the research could bene�t future patients. That’s altruism at its
�nest.”
Regardless of COVID-19 outbreak severity, the pandemic has forced physicians in many parts of the
United States to cut back substantially on PCa-related procedures at least for a few months, resulting
in a backlog of cases. The situation appears to be brightening, however. Even in places hard hit by
COVID-19, physicians say they have been whittling away at their backlogs and returning to the clinical
care they provided before the pandemic. It is too early to ascertain whether the delays in care caused
by the pandemic will adversely affect patient outcomes long-term, but physicians generally agree that
deferring prostate biopsies and de�nitive PCa treatment for a few months, at least for patients with
low-risk PCa, will not signi�cantly alter clinical outcomes. As healthcare services return to normal in
many places, the pandemic rages on in various regions of the United States as investigators work on
developing a COVID-19 vaccine and identifying safe and effective treatments.
References
1. COVID-19: Data. New York City Health Department website.
https://www1.nyc.gov/site/doh/covid/covid-19-data.page. Updated August 30, 2020. Accessed
August 31, 2020.
2. United States Washington Overview. Johns Hopkins University & Medicine Coronavirus
Resource Center website. https://coronavirus.jhu.edu/region/us/washington. Updated August
30, 2020. Accessed August 31, 2020.
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 10/12
3. United States Oregon Overview. Johns Hopkins University & Medicine Coronavirus Resource
Center website. https://coronavirus.jhu.edu/region/us/oregon. Updated August 30, 2020.
Accessed August 31, 2020.
4. United States Florida Overview. Johns Hopkins University & Medicine Coronavirus Resource
Center website. https://coronavirus.jhu.edu/region/us/�orida. Updated August 30, 2020.
Accessed August 31, 2020.
Renal & Urology News publishes timely news coverage of scienti�c developments of interest to nephrologists
and urologists, including in-depth coverage of all relevant medical conferences.
All of the news and departments from the print edition are fully archived on the site.
RESOURCES
Editorial Board
Reprints/Permissions
Issue Archive
USER CENTER
About Us
Contact Us
Advertise
Ad Choices
Back to Top
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 11/12
OTHER HAYMARKET MEDICAL WEBSITES
Cancer Therapy Advisor
Clinical Advisor
Clinical Pain Advisor
Dermatology Advisor
Endocrinology Advisor
Gastroenterology Advisor
Hematology Advisor
Infectious Disease Advisor
McKnight’s Long Term Care News
McKnight’s Senior Living
Medical Bag
MPR
myCME
Neurology Advisor
Oncology Nurse Advisor
Psychiatry Advisor
Pulmonology Advisor
Rheumatology Advisor
The Cardiology Advisor
Copyright © 2020 Haymarket Media, Inc. All Rights Reserved
This material may not be published, broadcast, rewritten or redistributed in any form without prior
authorization.
9/1/2020 Prostate Cancer Care Rebounding After COVID-19 Disruption - Renal and Urology News
https://www.renalandurologynews.com/home/web-exclusives/prostate-cancer-management-across-america/covid-19-pandemic-prostate-cancer-care/ 12/12
Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms &
Conditions.